# FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

> **NCT07004075** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Low-grade Glioma
- Pediatric Low-grade Gliomas
- pLGG With BRAF Alteration

## Interventions

- **DRUG:** Luvometinib
- **BIOLOGICAL:** Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide

## Key facts

- **NCT ID:** NCT07004075
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004075, "FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07004075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*